Cadila: Aggressive growth strategy - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cadila: Aggressive growth strategy

Dec 11, 2001

The performance of Cadila Healthcare, so far in the current year has been modest. It has been able to log less than 7% growth in topline for the first half of the current year. However, the company is on an acquisition spree to log faster growth through in-organic route. Recently, Cadila acquired Indiaís No.1 Cardiovascular product ĎAtení from Kopran for a total consideration of Rs 950 m. On last count ĎAtení had revenues in excess of Rs 380 m, logging a growth of more than 12% p.a. with more than 20% market share. The purchase of ĎAtení coupled with new product introductions in its newly commissioned Zydus Neuroscience division puts the company in the league of leading cardiovascular companies in India.

Zydus Neuroscience division has launched more than 8 products in the first half of the current year itself. Further, the company would also benefit from its acquisition of perpetual rights to market five leading brands from Asta (one of the promoters of German Remedies)

Cadila is also logging several co-marketing alliances to offer a better basket of products. It has already entered into several co-marketing alliances with Kopran, Ranbaxy and E-Merck for some of the drugs in therapeutic segments of anti-diabetics, CNS and other high growth segments. Remarkably, Cadila launched Once-a-Day version of Ofloxacin drug in alliance with Ranbaxy.

Further the acquisition of 28% stake in German Remedies last year is also expected to help the company in leveraging entry in to high margin therapeutic segments like respiratory, gynaecology and oncology, where German Remedies has a strong presence.

At the current market price of Rs 131, the stock is valued at 8 times FY02 expected earnings. These acquisitions are expected to help Cadila in logging faster growth rates going forward. However, the concern is the financing of these ventures may put an undue strain on the companyís balance sheet. The prospects of the company would depend on how fast the ambitious acquisitions pays off and performance of its new product introductions.


Equitymaster requests your view! Post a comment on "Cadila: Aggressive growth strategy". Click here!

  

More Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 28, 2020 11:01 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ACTAVIS COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS